EUVIMEDObjevte EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Artificial Intelligence and the Evolving Landscape of Immunopeptidomics

Thanh Hoa Vo iD, Edel McNeela, Orla O'Donovan, Sweta Rani, Jai Prakash Mehta

PROTEOMICS – Clinical Applications · 2025-11 · 19 (6)

DOI: 10.1002/prca.70018 ↗

At a glance

Übersichtsarbeit in PROTEOMICS – Clinical Applications, published online on 2025-07-31. Written by Thanh Hoa Vo and 4 co-authors. Institution: Department of Science, Pharmaceutical and Molecular Biotechnology Research Center (PMBRC), South East Technological University, Waterford, Ireland. Major MEDLINE topics: Artificial Intelligence, Peptides, Antigens, Neoplasm, Proteomics. Cited 15 times so far (Crossref); 106 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: South East Technological University.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Background Immunopeptidomics is the large‐scale study of peptides presented by major histocompatibility complex (MHC) molecules and plays a central role in neoantigen discovery and cancer immunotherapy. However, the complexity of mass spectrometry data, the diversity of peptide sources, and variability in immune responses present major challenges in this field. Review Focus In recent years, artificial intelligence (AI)‐based methods have become central to advancing key steps in immunopeptidomics. It has enabled advances in de novo sequencing, peptide‐spectrum matching, spectrum prediction, MHC binding prediction, and T cell recognition modeling. In this review, we examine these applications in detail, highlighting how AI is integrated into each stage of the immunopeptidomics workflow. Case Study This review presents a focused case study on breast cancer, a heterogeneous and historically less immunogenic tumor type, to examine how AI may help overcome limitations in identifying actionable neoantigens. Challenges and Future Perspectives We discuss current bottlenecks, including challenges in modeling noncanonical peptides, accounting for antigen processing defects, and avoiding on‐target off‐tumor toxicity. Finally, we outline future directions for improving AI models to support both personalized and off‐the‐shelf immunotherapy strategies. Summary Artificial intelligence (AI) is reshaping the immunopeptidomics landscape by overcoming challenges in peptide identification, immunogenicity prediction, and neoantigen prioritization. This review highlights how AI‐based tools enhance the detection of MHC‐bound peptides—including low‐abundance, noncanonical, and post‐translationally modified epitopes and improve peptide‐spectrum matching and T‐cell epitope prediction. By demonstrating a case study on applications in breast cancer, we illustrate the potential of AI to reveal hidden immunogenic features in tumors previously likely considered immunologically “cold.” These advancements open new opportunities for expanding neoantigen discovery pipelines and optimizing cancer immunotherapies. Looking ahead, the application of deep learning, transfer learning, and integrated multi‐omics models may further elevate the accuracy and scalability of immunopeptidomics, enabling more effective and inclusive vaccine and T‐cell therapy development.

Subjects

MeSH terms (MEDLINE)

Artificial IntelligencePeptidesAntigens, NeoplasmProteomicsHumansBreast NeoplasmsImmunotherapy

Author keywords

artificial intelligencecancer vaccineimmunopeptidomicsimmunotherapyneoantigen

Substances

PeptidesAntigens, Neoplasm

Authors and institutions

  • Department of Science, Pharmaceutical and Molecular Biotechnology Research Center (PMBRC), South East Technological University, Waterford, Ireland.
  • Department of Applied Science, South East Technological University, Carlow, Ireland.

ORCID profiles: Thanh Hoa Vo

Funding

  • South East Technological University

Cite

APA

Vo, T. H., McNeela, E., O'Donovan, O., Rani, S., & Mehta, J. P. (2025). Artificial Intelligence and the Evolving Landscape of Immunopeptidomics. PROTEOMICS – Clinical Applications, 19(6). https://doi.org/10.1002/prca.70018

Vancouver

Vo TH, McNeela E, O'Donovan O, Rani S, Mehta JP. Artificial Intelligence and the Evolving Landscape of Immunopeptidomics. PROTEOMICS – Clinical Applications. 2025;19(6). doi:10.1002/prca.70018

BibTeX
@article{Vo2025,
  author = {Vo, Thanh Hoa and McNeela, Edel and O'Donovan, Orla and Rani, Sweta and Mehta, Jai Prakash},
  title = {Artificial Intelligence and the Evolving Landscape of Immunopeptidomics},
  journal = {PROTEOMICS – Clinical Applications},
  year = {2025},
  volume = {19},
  number = {6},
  doi = {10.1002/prca.70018}
}
Start for free →